[Experimental and clinical studies of cefotiam for the treatment of otorhinolaryngological infections].
Basic and clinical studies on cefotiam (CTM) for the infectious diseases in otorhinolaryngological field were performed and the following results were obtained. The peak value in the serum level of CTM was 18.05 micrograms/ml by 0.5 g administration and 35.2 micrograms/ml by 1 g at 30 minutes after a single intravenous injection. CTM was rapidly excreted from the blood after injection and was detected a little amount in serum at 6 hours after the administration. Tissue concentrations of the drug into palatine tonsil and the mucous membrane of the nasal cavity or maxillary sinus were seen in relatively rapid and good manner. Chemotherapeutic results excepting Pseudomonas aeruginosa infections (3 cases) were excellent in 2 cases, good in 7 cases and poor in 3 cases of 12 patients with the infectious diseases in otorhinolaryngological field. No adverse effects and abnormal values in the laboratory findings were revealed in every patients.
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D015310:Cefotiam; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D014066:Palatine Tonsil / Q000378:metabolism; D010256:Paranasal Sinuses / Q000378:metabolism; D014018:Tissue Distribution
D015310:Cefotiam; D002439:Cefotaxime